Brooklyn, NY – According to filings with the U.S. Securities and Exchange Commission, AzurRx BioPharma is raising $8,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Daniel Schneiderman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AzurRx BioPharma

AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection.  The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

To learn more about AzurRx BioPharma, visit http://www.azurrx.com/

Contact:
Daniel Schneiderman, Chief Financial Officer
646-699-7855
https://www.linkedin.com/in/danschneiderman/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved